Guidelines for the use of tacrine in Alzheimer's disease: Clinical application and effectiveness

Constantine G. Lyketsos, Kirsten Corazzini, Cynthia D. Steele, Marilyn F. Kraus

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


The efficacy of tacrine for treatment of Alzheimer's has been demonstrated in several clinical trials but has not been assessed in cases complicated by medical and psychiatric comorbidities. Additionally, the benefit-risk ratio of tacrine is small, so it is best administered with carefully developed guidelines that specify this ratio for patients and families. On the basis of guidelines developed for the Johns Hopkins Dementia Research Clinic, tacrine treatment was offered to 162 patients with probable Alzheimer's. Only 35 accepted, and only 22 continued on tacrine beyond 3 months. The latter group declined by 1.36 points over 1 year on the Mini-Mental State Examination, significantly less than expected. The authors conclude that, if used in the context of clinical guidelines, tacrine is an effective treatment for Alzheimer's.

Original languageEnglish (US)
Pages (from-to)67-73
Number of pages7
JournalJournal of Neuropsychiatry and Clinical Neurosciences
Issue number1
StatePublished - Jan 1 1996

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'Guidelines for the use of tacrine in Alzheimer's disease: Clinical application and effectiveness'. Together they form a unique fingerprint.

Cite this